|  | Stage IA | Stage IB | |
---|---|---|---|---|
Prescribed dose (in 4 fractions) | All | 44 Gy | 48 Gy | 52 Gy |
Patient number | 124 | 2 | 85 | 37 |
Age (years) | Â | Â | Â | Â |
   Range (median) | 29-89 (77) | 67, 70 | 58-87 (77) | 29-89 (78) |
Gender | Â | Â | Â | Â |
   Male | 84 | 1 | 54 | 29 |
   Female | 40 | 1 | 31 | 8 |
Performance status | Â | Â | Â | Â |
   0 | 65 | 2 | 47 | 16 |
   1 | 48 | 0 | 31 | 17 |
   2 | 11 | 0 | 7 | 4 |
Tumor size (mm) | Â | Â | Â | Â |
   Range (median) | 12-55 (27) | 12, 14 | 15-34 (24) | 31-55 (35) |
Operability | Â | Â | Â | Â |
   Operable | 40 | 2 | 27 | 11 |
   Non-operable | 84 | 0 | 58 | 26 |
Histology | Â | Â | Â | Â |
   Adenocarcinoma | 66 | 2 | 46 | 18 |
   Squamous cell carcinoma | 35 | 0 | 19 | 16 |
   Unclassified NSCLC | 13 | 0 | 10 | 3 |
   Unproven | 10 | 0 | 10 | 0 |
Tumor location | Â | Â | Â | Â |
   Central | 29 | 0 | 18 | 11 |
   Peripheral | 95 | 2 | 67 | 26 |